The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Official Title: A Randomized, Open-Label, Multi-Center, Phase Ⅲ Clinical Study of Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Study ID: NCT04639180
Brief Summary: A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Guangxi Medical University Affiliated Tumor Hospital, Nanjin, Guangzhou, China
Guizhou Cancer Hospital, Guiyang, Guizhou, China
Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China